EMA Authorised: Lupkynis (voclosporin) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

EMA authorised Lupkynis (voclosporin) for lupus nephritis, with Otsuka Pharmaceutical Netherlands B.V. as MAH; decision dated 11/08/2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• LUPKYNIS (voclosporin)

Snippet

Status: Authorised. Therapeutic area: Lupus Nephritis. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 11/08/2026